drug · small molecule

FILSPARI

updated 3mo ago

by $TVTX Travere Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for iga glomerulonephritis and 3 investigational indications.

targets

Endothelin-1 receptorType-1 angiotensin II receptor

all catalysts(0)

nothing on the calendar yet

Trials studying FILSPARI

phase1Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinurianot yet recruitingn=20
phase3A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathyactive not recruitingn=406
phase3Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)completedn=371
phase4Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosisrecruitingn=20
phase2Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseasesrecruitingn=67
phase2A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANcompletedn=48
phase2ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)active not recruitingn=32
phase2Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosiscompletedn=109

more trials →

News(1)

Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…
endpoints · 2mo ago

brand

FILSPARI

trade names

Filspari

generic

SPARSENTAN

MOA

12.1 Mechanism of Action Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ET A R) and the angiotensin II type 1 receptor (AT 1 R). Sparsentan has high affinity for both the ET A R (Ki= 12.8 nM) and the AT 1 R (Ki=0.36 nM), and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. Endothelin 1 and angiotensin II are thought to be involved in the pathogenesis of IgAN and FSGS via the ET A R and AT 1 R, respectively.

indication

1 INDICATIONS AND USAGE FILSPARI is an endothelin and angiotensin II receptor antagonist indicated: • To slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression ( 1.1 , 12.1 , 14.1 ). • To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome ( 1.2 , 12.1 , 14.2 ). 1.1 Immunoglobulin A Nephropathy FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.1 )]. 1.2 Focal Segmental Glomerulosclerosis FILSPARI is indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.2 )].

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 21m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

FILSPARI

updated 3mo ago

by $TVTX Travere Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for iga glomerulonephritis and 3 investigational indications.

targets

Endothelin-1 receptorType-1 angiotensin II receptor

all catalysts(0)

nothing on the calendar yet

Trials studying FILSPARI

phase1Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinurianot yet recruitingn=20
phase3A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathyactive not recruitingn=406
phase3Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)completedn=371
phase4Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosisrecruitingn=20
phase2Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseasesrecruitingn=67
phase2A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANcompletedn=48
phase2ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)active not recruitingn=32
phase2Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosiscompletedn=109

more trials →

News(1)

Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…
endpoints · 2mo ago

brand

FILSPARI

trade names

Filspari

generic

SPARSENTAN

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 21m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

FILSPARI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying FILSPARI

News(1)

Report a data issue

comments(0)

FILSPARI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying FILSPARI

News(1)

Report a data issue

comments(0)